Smith & Nephew plc (SN.L)
| Previous Close | 1,125.00 |
| Open | 1,123.00 |
| Bid | 1,123.00 x 0 |
| Ask | 1,123.50 x 0 |
| Day's Range | 1,120.50 - 1,132.11 |
| 52 Week Range | 887.00 - 1,195.50 |
| Volume | |
| Avg. Volume | 2,613,191 |
| Market Cap | 9.783B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 48.78 |
| EPS (TTM) | 0.23 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | 0.30 (2.70%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | 12.97 |
ZacksShould Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Simply Wall St.Admiral Group And 2 More UK Exchange Stocks Estimated As Below Intrinsic Value
Recent performance of the United Kingdom's stock market has been notably affected by external economic factors, including weak trade data from China which has led to declines in the FTSE 100 and FTSE 250 indices. Amid these challenging conditions, identifying stocks that are potentially undervalued becomes particularly crucial as they may offer resilience or recovery potential when broader markets are faltering.
ZacksSmith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
